November 14, 2016 07:03 AM EST

Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help

John Carroll

Editor & Founder

Shares of Dynavax headed south Monday morning after the biotech notified investors that the FDA has rejected its application to market the hepatitis B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help

John Carroll

Editor & Founder

Sign up to read this article for free.

BridgeBio ends development of gene therapy for adrenal gland disorder

Sanofi, Regeneron to refile Dupixent for skin condition after new study win

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

Radiant Bio snags $35M for antibody platform, with GSK and Regeneron partnerships

Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

GSK discontinues herpes therapeutic vaccine after Phase 2 disappointment

Dy­navax shares crater af­ter the FDA re­jects Hep­lisav-B, again, and CEO sig­nals for help

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Bridge­Bio ends de­vel­op­ment of gene ther­a­py for adren­al gland dis­or­der

Sanofi, Re­gen­eron to re­file Dupix­ent for skin con­di­tion af­ter new study win

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Ra­di­ant Bio snags $35M for an­ti­body plat­form, with GSK and Re­gen­eron part­ner­ships

Novo's oral amy­cretin could lead to more weight loss be­yond 12 weeks, ac­cord­ing to ear­ly-stage tri­al

GSK dis­con­tin­ues her­pes ther­a­peu­tic vac­cine af­ter Phase 2 dis­ap­point­ment

Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help

BridgeBio ends development of gene therapy for adrenal gland disorder

Sanofi, Regeneron to refile Dupixent for skin condition after new study win

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

Radiant Bio snags $35M for antibody platform, with GSK and Regeneron partnerships

Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

GSK discontinues herpes therapeutic vaccine after Phase 2 disappointment